Can technology improve adherence to long-term therapies?
BACKGROUND
Therapeutic nonadherence is defined as the lack of equivalence between the behavior of the patients and their prescribed medical treatment. Consequences of nonadherence include not only health outcomes, but also cost saving. Thus, this issue gets paramount importance in contemporary medicine.


METHODS
The aim of this article is to discuss the relationships between technology and adherence by asking the following three questions. (1) How can technology be used to monitor patient adherence? (2) Considering the mechanisms of nonadherence in chronic diseases, is there room for technology in interventions aimed to improve patient adherence? (3) What about adherence to technology in diabetes care?


CONCLUSIONS
Technology may help improve adherence to long-term therapies by (1) giving a concrete representation of adherence rewards, (2) overcoming immediate obstacles to adherence, such as the fear of hypoglycemia, and (3) providing an opportunity for patient-doctor conversations. This assumes, however, that both the patient and the doctor are convinced that technologies are useful.
Department of Endocrinology, Diabetes and Metabolic Diseases, Avicenne Hospital, Bobigny, France. gerard.reach@avc.aphp.fr
Gérard
G
Reach
D001709:Biotechnology / Q000639:trends*; D002908:Chronic Disease; D003142:Communication; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000523:psychology*; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D018670:Monitoring, Ambulatory / Q000379:methods*; D010349:Patient Compliance / Q000523:psychology*; D010817:Physician-Patient Relations; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013997:Time Factors
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D013453:Sulfonylurea Compounds